Related references
Note: Only part of the references are listed.The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry
Sevda Hassan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative
Pavan K. Bendapudi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why?
James N. George
TRANSFUSION (2015)
How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome
Spero R. Cataland et al.
BLOOD (2014)
Syndromes of Thrombotic Microangiopathy
James N. George et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP)
Neil Shah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Guidelines on the Use of Therapeutic Apheresis in Clinical PracticeEvidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
Joseph Schwartz et al.
JOURNAL OF CLINICAL APHERESIS (2013)
Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies
Peter C. Austin
PHARMACEUTICAL STATISTICS (2011)
Survival and relapse in patients with thrombotic thrombocytopenic purpura
Johanna A. Kremer Hovinga et al.
BLOOD (2010)
How I treat patients with thrombotic thrombocytopenic purpura: 2010
James N. George
BLOOD (2010)
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
Peter C. Austin
STATISTICS IN MEDICINE (2009)
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura
J. Evan Sadler
BLOOD (2008)
A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003
Peter C. Austin
STATISTICS IN MEDICINE (2008)
The design versus the analysis of observational studies for causal effects:: Parallels with the design of randomized trials
Donald B. Rubin
STATISTICS IN MEDICINE (2007)
Variable selection for propensity score models
M. Alan Brookhart et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2006)
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay
K Kokame et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma
JN George et al.
TRANSFUSION (2004)
VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13
K Kokame et al.
BLOOD (2004)
Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura
XL Zheng et al.
BLOOD (2004)
Von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: The Swiss experience
JAK Hovinga et al.
SEMINARS IN HEMATOLOGY (2004)
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome:: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients
SK Vesely et al.
BLOOD (2003)
Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity
Y Mori et al.
TRANSFUSION (2002)
Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome
MA Rizvi et al.
TRANSFUSION (2000)
Share Paper
